Medicinova (MNOV) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medicinova is the larger company by market cap ($67.1 million vs $66.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | PLYX |
|---|---|---|
| Share price | $1.31 | $1.33 |
| Market cap | $67.11M | $66.30M |
| 1-day change | +3.15% | -11.92% |
| YTD return | 0.00% | — |
| 1-year return | -8.39% | — |
| 5-year return | -59.32% | — |
| EPS (TTM) | $-0.21 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $409.66K | — |
| Net income (latest FY) | $-12.00M | $-8.98M |
| Operating margin | -3242.47% | — |
| Net margin | -2928.78% | — |
| 52-week high | $3.90 | $48.91 |
| 52-week low | $1.22 | $1.30 |
| Distance from 52-week high | -66.41% | -97.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +529.77% | +463.91% |
| Average volume | 334.96K | 36.42K |
| Shares outstanding | 51.23M | 49.85M |
| Employees | 6 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
MNOV vs PLYX FAQ
Which is bigger, Medicinova or Polaryx Therapeutics?
Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $66.30M for Polaryx Therapeutics (PLYX).
Are Medicinova and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.